The Effect of RAS Modulation on Organ Support-Free Days in Patients With COVID-19

RAS dysregulation in SARS-CoV-2 infection may have increased the relative activity of angiotensin 2. Two clinical trials found that RAS modulation with either of these drugs did not improve oxygen-free days or number of days alive versus placebo after one month. The third original research article by the writing committee for the remap CAP investigators reports on the effect of the angiotENSin converting enzyme inhibitor initiation or angiotensinsin receptor blocker (ARB) On organ support-free days in patients hospitalized with COVID-19, researchers found that among critically ill patients, initiation of an ARB did not improve and likely worsened clinical outcomes.